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Abstract
Background: We previously demonstrated that single nucleotide polymorphism (SNP) and haplotypes were associated with
aspirin hypersensitivity in asthmatics. We investigated the genetic effects of the SNPs and haplotypes on the expression of the
CysLTR2 gene.
Methods: We measured CysLTR2 protein and mRNA expression in EB virus-infected B cell lines from asthmatics having ht1+/
+ and ht2+/+. A gel retardation assay was used to identify nuclear protein binding to the c.-819 promoter site. The function of
promoter and 3'-UTR were assessed using pGL3 luciferase and pEGFP reporter system, respectively.
Results: We found that the expression of CysLTR2 protein was higher in B cell lines of asthmatics having ht2+/+ than in those
having ht1+/+. PMA/ionomycin induced higher mRNA expression of CysLTR2 in B cell lines from ht2+/+ asthmatics than those
from ht1+/+ asthmatics. A nuclear protein from the B cell lines showed stronger DNA binding affinity with a probe containing c.-
819T than one containing c.-819G. The luciferase activity of the c.-819T type of CysLTR2 promoter was higher than that of the
c.-819G type. EGFP expression was higher in the EGFP-c.2078T 3'-UTR fusion construct than in the c.2078C construct.
Conclusion: The sequence variants of CysLTR2 may affect its transcription and the stability of its mRNA, resulting in altered
expression of CysLTR2 protein, which in turn causes some asthmatics to be susceptible to aspirin hypersensitivity.
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Background
Aspirin-intolerant asthma (AIA) refers to the development
of bronchoconstriction in asthmatics following the inges-
tion of aspirin or other non-steroidal anti-inflammatory
drugs (NSAIDs). This syndrome is characterized by the
'aspirin triad' [1] syndrome of aspirin hypersensitivity,
bronchial asthma, and chronic rhinosinusitis with nasal
polyposis. A two-compartment model has been proposed
in which both the augmentation of cysteinyl leukotriene
(CysLT) production and the overexpression of the CysLT
receptor on inflammatory cells occur within the respira-
tory tract [2]. The overproduction of CysLTs has been
demonstrated in the airways and circulation of asthmatics
who are intolerant to aspirin [3-5]. CysLTs are important
inflammatory mediators in the development of asthma,
as they mediate bronchoconstriction while increasing
mucus secretion, vascular permeability and cellular infil-
tration [6]. CysLTs exert their biological actions by bind-
ing two types of G-protein-coupled seven-transmembrane
receptors: cysteinyl leukotriene receptor 1 (CysLTR1; MIM
300201), which is sensitive to the asthma drugs montelu-
kast, zafirlukast and pranlukast [7,8] and CysLTR2 [9].
CysLTR2 has been documented to be expressed in lung
interstitial macrophage [10], pulmonary vascular smooth
muscle, endothelium [11-13], eosinophils [14], mast cells
[15], B and T lymphocytes [16,17], raising the possibility
that CysLTR2 may have an important role in allergic
inflammation. Particularly, CysLTR2 may have important
role in remodeling and fibrosis pathways in B lym-
phocytes. Furthermore, CysLTR2 is located on
chromosome13q14.2-21.1, near a locus known to be
associated with the risk of asthma in various population.
CysLTR2 play a disease-regulating role in glands and epi-
thelium of rhinosinusitis, particularly aspirin-sensitive
disease [18]. In addition, Cysteinyl-LT signaling may pro-
vide a key balance between a release of endothelium-
dependent relaxant and constricting factors in endothe-
lium dysfunction [19]. The endothelial CysLTR2 is rapidly
down-regulated by pro-inflammatory stimuli in Myocar-
dial Ischemia [20]. A role for CysLTR2 is mediated the cor-
onary constriction in patients with coronary artery disease
[21]. CysLTR2 may also contribute to neurological
inflammation in the human brain and the adrenal glands
of neuroendocrine system [22]. We previously identified
four sequence variants of the CysLTR2 gene: one in the
promoter (c.-819G>T, rs7324991), two in the 3'-flanking
region (c.2078C>T and c.2534A>G, novel and rs912278),
and one downstream of the gene (c.2545+297A>G,
rs2407249) [20]. We also revealed that asthmatics having
rare alleles for c.-819G>T, c.2078C>T or c.2534A>G exhib-
ited a more pronounced drop in FEV1 by aspirin provoca-
tion than those who carried the common alleles (P = 0.03-
0.009). In previously study, five haplotypes (GCAA,
TTGA, TCGG, TCAA and others) were constructed. The
frequencies of these five haplotypes in the Korean popula-
tion (N = 642), African-American (N = 50) and Caucasian
(N = 50) were: 0.495, 0.14, 0.44 (ht1), 0.346, 0.02, 0.23
(ht2), 0.083, 0.17, 0.23 (ht3), 0.07, 0.6, 0.09 (ht4) and
0.006, 0.07, 0.01 (others) in Korean, African-American
and Caucasian, respectively. Significant differences in the
frequencies of the SNPs and haplotypes were observed
among the three ethnic groups. The linkage disequilib-
rium coefficients (|D'|) and r2 among the SNPs were cal-
culated for all of the study subjects. Strong LDs were noted
between SNPs (|D'| > 0.97) in Korean. Complete LDs
were observed between SNPs (c.-819 G>T, c.2078 C>T
and c.2534 A>G) in Caucasian (|D'| > 0.90). In African-
American, between SNPs (c.2534 A>G and
c.2545+297A>G) were observed complete LDs (|D'| >
0.92) [20]. Subjects with the ht2 haplotype, which is com-
posed of the rare alleles for the three SNPs (TTG), were
susceptible to aspirin intolerance. These results suggest
that sequence variants on the promoter (c.-819G>T) of
CysLTR2 may affect the efficiency of its transcription with
tight linkage to 3'-UTR variations or that the SNPs them-
selves on 3'-UTR may affect the stability of its mRNA [20].
The functional effects of these SNPs on transcription
should be identified. Here, we investigated the genetic
effect of the promoter and the 3'-UTR polymorphisms of
CysLTR2 at the transcriptional and translational levels of
the gene.
Results
Flow cytometric analysis of CysLTR2 expression between 
haplotypes 1 and 2
To investigate the effect of the SNPs on the production of
CysLTR2 protein in the B cell lines, we measured CysLTR2
protein levels on the surface of B cell lines for ht1
homozygotes (ht1+/+, N = 8) and ht2 homozygotes (ht2+/
+, N = 9) using immunofluorescence staining and flow
cytometric analysis (Figure 1). Approximately 50% of
EBV-infected B cells expressed CysLTR2 on their surface
(Figure 1A). The positive rate of CysLTR2 on the B cell
lines was not significantly different between the two hap-
lotypes (ht1+/+; 46.96 ± 5.10% vs. ht2+/+; 48.26 ± 7.36%, P
> 0.05; Figure 1B). The amount of CysLTR2 protein
among CysLTR2 positive B cells, however, was signifi-
cantly different (Figure 1C). The mean fluorescence inten-
sity was significantly higher in B cells of the subjects
having ht2+/+ than in those having ht1+/+ (5.07 ± 0.21 vs.
3.90 ± 0.45, P = 0.04). These results indicate that single
nucleotide polymorphisms on the promoter or 3'-UTR
region may affect protein expression of the CysLTR2 gene.
Comparison of mRNA levels of the CysLTR2 gene 
between haplotypes 1 and 2
To investigate the genetic effect of these polymorphisms
on the mRNA expression of CysLTR2 in B cell lines, we
measured the CysLTR2 mRNA levels between ht1+/+and
ht2+/+ by RT-PCR. Semi-quantitation of CysLTR2 mRNABMC Medical Genetics 2009, 10:106 http://www.biomedcentral.com/1471-2350/10/106
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expression was measured by the intensity of CysLTR2 RT-
PCR product corrected by the intensity of GAPDH. The
expression level of CysLTR2 mRNA in unstimulated B cell
lines was similar in ht2+/+ (N = 6) and ht1+/+ (N = 6, P
>0.05; Figure 2A); however, PMA/ionomycin markedly
induced mRNA expression of the CysLTR2 gene in EBV-
infected B cells of ht2+/+ (N = 6) relative to ht1+/+ (N = 6, P
= 0.016; Figure 2B). These results indicate that the protein
expression of the CysLTR2 gene may be regulated at tran-
scriptional levels.
Comparison of promoter activity between T and G type of 
CysLTR2 promoter c.-819 T>G
Because the SNPs of CysLTR2  haplotype 1 and 2 are
located on the promoter region and on the 3'-UTR region,
we investigated the individual effect of these two SNPs on
CysLTR2 mRNA expression. First, we compared the activ-
ities of promoters possessing c.-819T or G by luciferase
reporter assay as described in the Methods.
Due to 293 T cells expressing CysLTR2 mRNA by PMA/
ionomycin stimulation (Figure 3A), the CysLTR2  pro-
moter-luciferase constructs were transfected into the cells
and the differences in luciferase activities between c.-819G
and T were analyzed. Luciferase activity was normalized
by  -galactosidase activity co-transfected as an internal
control. In the absence of stimulation, no difference was
observed in luciferase activities between genotypes (Fig-
ure 3B, c.-819G; 41.83 ± 6.01 vs. c.-819T; 38.12 ± 2.28, P
Flow cytometric analysis of CysLTR2 expression on B cell  lines between haplotype 1 homozygote (ht1+/+, GCAA: c.-- 819G>T, c.2078C>T, c.2534A>G and c.2545+297A>G) and  haplotype 2 homozygote (ht2+/+, TTGG) Figure 1
Flow cytometric analysis of CysLTR2 expression on B 
cell lines between haplotype 1 homozygote (ht1+/+, 
GCAA: c.--819G>T, c.2078C>T, c.2534A>G and 
c.2545+297A>G) and haplotype 2 homozygote (ht2+/+, 
TTGG). (A) Histogram of CysLTR2 protein expression on 
the EBV-infected B cell line. Immunofluorescence staining 
was performed using anti-human CysLTR2 Ab and FITC-con-
jugated secondary Ab as described in the Methods. The histo-
gram is a representative of 17 independent experiments. (B) 
Ratio of CysLTR2 positive cells of the EBV-infected B cell 
lines having ht1+/+ (n = 8) or ht2+/+ (n = 9). (C) Mean fluores-
cence intensity of CysLTR2 expression of the same B cell 
lines. The ratio of mean FL1 channel values was determined 
as the FL1 level of CysLTR2 staining to that of isotype-
matched control staining. P values were calculated by a 
Mann--Whitney U-test.
CysLTR2 mRNA expression of ht1+/+ or ht2+/+ EBV-infected  B cell lines Figure 2
CysLTR2 mRNA expression of ht1+/+ or ht2+/+ EBV-
infected B cell lines. After B cell lines were cultured with 
or without PMA (10 ng/ml)/ionomycin (2 M) for 24 h, the 
mRNA expression of CysLTR2 was analyzed by RT--PCR. 
(A) The intensities of PCR products were measured using a 
densitometer, and compared between ht1+/+(n = 6) and ht2+/
+ (n = 6) B cell lines. (B) The data are presented as the mean 
± SEM. * P < 0.05 calculated using a Mann--Whitney U-test 
for comparing PMA/ionomycin-treated ht1+/+ or ht2+/+ B cell 
lines. † P < 0.01 calculated using Wilcoxon's signed-ranks test 
for comparing PMA/ionomycin-treated and untreated ht2+/+ 
B cell lines.
Promoter (c.--819T>G) activity of the human CysLTR2 gene Figure 3
Promoter (c.--819T>G) activity of the human 
CysLTR2 gene. The 293 T cells expressed CysLTR2, which 
increased with 24 h PMA/ionomycin stimulation (A) The pro-
moter region of CysLTR2 having c.--819T or c.--819G was 
inserted into the pGL3 basic vector and the constructs and 
-galactosidase expression vector were co-transfected into 
293 T cells by lipofection. Twenty-four hours after transfec-
tion, the transfected cells (2.5 × 105/ml) were stimulated with 
10 ng/ml of PMA and 2 mM of ionomycin for 24 h. Luciferase 
activities were measure by luminometer and normalized by 
-galactosidase activities as internal controls. (B) The data 
are presented as the mean ± SEM of normalized luciferase 
activities (the ratio of luciferase activities to -galactosidase 
activities) of six independent experiments. *P < 0.01 calcu-
lated using a Mann--Whitney U-test for comparing luciferase 
activities between PMA/ionomycin-treated c.--819G and c.--
819T promoter. † P < 0.05 calculated using Wilcoxon's 
signed-ranks test for comparing luciferase activities of PMA/
ionomycin-treated and untreated c.819T promoter.BMC Medical Genetics 2009, 10:106 http://www.biomedcentral.com/1471-2350/10/106
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> 0.05). However, PMA/ionomycin stimulation signifi-
cantly induced luciferase activity in c.-819T but not in the
G type. As a result, the luciferase activity of the c.-819T
type of the CysLTR2  promoter was significantly higher
than that of the c.-819G type (60.79 ± 4.21 vs. 35.30 ±
2.70, respectively, P = 0.002). These data suggest that tran-
scription of the CysLTR2 gene may be differently regulated
when stimulated according to the nucleotide polymor-
phism at the -819 locus on the promoter.
Nuclear factor binding site on the region of the promoter 
containing CysLTR2 c.-819T>G
To confirm whether the locus on the promoter of CysLTR2
(c.-819G>T) provided the binding sites for a transcription
factor, gel shift assays were performed using the nuclear
extract from EBV-infected B cells. DNA-protein complexes
were detected with the probe for CysLTR2 c.-819T (Figure
4C). The intensity of this complex was higher when
hybridized with the probe for c.-819T than with the probe
for the c.-819G and decreased through competition with
the unlabeled probe of each type. Nuclear extract from the
PMA/ionomycin-stimulated B cell lines showed stronger
DNA-protein binding affinity in the T type of probe than
the unstimulated B cell lines. This indicates that the
CysLTR2 promoter region around c.-819T may be the binding
site for a transcription factor. Since a TFSEARCH search
revealed putative binding sites for several candidate tran-
scription factors around the c.-819T>G  allele, such as
HFH-2 and SRY (Figure 4A and 4B), we performed a
supershift assay for SRY and Foxd3, which is the human
homolog of HFH-2. However, neither HFH-2 nor SRY
showed the supershift in EMSA (data not shown).
Comparison of 3'-UTR activity between C and T types of 
the CysLTR2 3'- UTR c.2078C>T
To evaluate the effect due to sequence variance of 3'-UTR
c.2078C>T on CysLTR2 protein expression, the fluores-
cence intensity of 293 T cell lines transfected with each
type (c.2078C or T) of EGFP-CysLTR2 3'-UTR fusion con-
struct was analyzed using flow cytometry (Figure 5A). The
EGFP expression levels of the EGFP-CysLTR2  3'-UTR
fusion constructs were analyzed as the mean fluorescence
intensity of EGFP of all cells analyzed. On flow cytometry
analysis, side scatter and forward scatter were not different
between the two cell types. The relative EGFP expression
level of the 3'-UTR (c.2078T) fusion construct was signifi-
cantly higher than that of the c.2078C construct (Figure
5B; 0.96 ± 0.07 vs. 0.48 ± 0.06, respectively, P = 0.002),
indicating that the mRNA stability of the c.2078T type of
CysLTR2 3'-UTR was higher than that of c.2078C.
Gel shift assay for SNP CysLTR2 c.--819 using nuclear extract  from B cell lines Figure 4
Gel shift assay for SNP CysLTR2 c.--819 using nuclear 
extract from B cell lines. Putative transcription factor 
binding site of c.--819T (A) and G type (B) are indicated by 
underlines (TFSEARCH Searching Transcriptional Factor 
Binding Sites V1.3). Gel shift assays were performed using 
nuclear extracts of EBV-infected B cell lines and dsDNA 
probes possessing c.--819G or T (C). One million cells per 
milliliter of EBV-infected B cell lines established from asth-
matics were cultured for 24 h with or without 10 ng/ml of 
PMA and 2 M of ionomycin. The nuclear extracts of B cell 
lines were incubated with the 32P-labeled probes, the 
sequences of which included each genotype of c.--819 (see 
Methods). To identify specific binding complexes, nuclear 
extract from B cell lines was preincubated with the unlabeled 
probe 10 min before the addition of the labeled probe. The 
open arrow shows the specific DNA--protein complexes and 
the filled arrow indicates the free unbound probe. Arrow-
heads denote nonspecific DNA--protein complexes. These 
data are representative of six independent experiments.
Flow cytometric analysis of the effects of the human CysLTR2  gene 3'-UTR on EGFP protein expression Figure 5
Flow cytometric analysis of the effects of the human 
CysLTR2 gene 3'-UTR on EGFP protein expression. 
The 3'-UTR region possessing each genotype (C or T) on 
c.2078 was inserted between the EGFP coding region and 
SV40 poly A site as described in the Methods. After each con-
struct was co-transfected with the -galactosidase expres-
sion vector as an internal control into 293 T cell lines, the 
expression levels of the EGFP protein were measured using a 
flow cytometer (A) and the fluorescence intensity of each 
construct was compared (B). The data are presented as the 
mean ± SEM of relative FL1 values (the ratio of EGFP--
CysLTR2 3'-UTR fusion constructs to naive pEGFP-N1 vec-
tor) of six independent experiments. The P value was calcu-
lated using a Mann--Whitney U-test.BMC Medical Genetics 2009, 10:106 http://www.biomedcentral.com/1471-2350/10/106
Page 5 of 9
(page number not for citation purposes)
Discussion
We demonstrated that the sequence variant on the pro-
moter (c.-819G>T) of the CysLTR2 gene affects the effi-
ciency of its transcription and the sequence variant on the
3'-UTR (c.2078C>T)  modulates mRNA degradation,
resulting in different expressions of CysLTR2  protein
according to the gene genotypes. We previously identified
three novel SNPs in the promoter and 3'-untranslated
region of CysLTR2. Three SNPs (c.-819G>T, c.2078C>T,
and c.2534A>G) and ht1 [G-C-A-A], ht2 [T-T-G-A] were
strongly associated with the drop in FEV1 induced by aspi-
rin challenge in asthmatics [20]. To identify the functional
effects of these SNPs on transcription and translation of
the CysLTR2 gene, we first measured the protein expres-
sion of the CysLTR2  gene. CysLTR2 is known to be
expressed by lung interstitial macrophages [10], pulmo-
nary vascular smooth muscle, endothelium [11-13], eosi-
nophils [14] and mast cells [15]. These cells are difficult to
obtain and maintain from our asthmatics subjects, so we
used immortalized B cells induced by EB virus from sub-
jects whose genotypes had been analyzed in a previous
study [20]. We demonstrated that the B cell lines having
ht2+/+  had a higher translational and transcriptional
expression levels of CysLTR2 than those having ht1+/+,
especially when stimulated (Figure 1 and 2). These results
indicate that the genetic differences affect the amount of
protein and mRNA expression in the CysLTR2 gene. In our
previous studies, ht2 homozygote asthmatics showed the
highest responses to aspirin challenge, while ht1 homozy-
gotes showed the lowest responses [20]. Taken together,
these data suggest that the greater response to aspirin chal-
lenge in asthmatics may be due to higher expression of
CysLTR2 protein on the B cells and presumably on the
other CysLTR2 gene-expressing cells, such as lung intersti-
tial macrophages [10], eosinophils [14] and mast cells
[15].
Next, we assessed the regulating mechanisms of the three
SNPs (c.-819G>T, c.2078C>T and c.2534A>G) on CysLTR2
protein expression using promoter activity assays and 3'-
UTR function analysis because the sequence variants on
the promoter (c.-819G>T) of the CysLTR2 gene may affect
the efficiency of its transcription and the SNPs on the 3'-
UTR may affect the stability of its mRNA. Luciferase activ-
ity of the CysLTR2 promoter was higher in the T type trans-
fected 293T cells than in the G type, which indicates that
the sequence variants on the promoter are regulators for
CysLTR2 gene expression (Figure 3). The genetic role of
the promoter (c.-819G>T) was demonstrated by the
nuclear protein binding assay (Figure 4). The binding
affinity of this DNA-binding factor was higher for c.-819T
than for c.-819G with or without PMA/ionophore stimula-
tion (Figure 4). In the steady state, this DNA-binding fac-
tor may bind constitutively to the promoter close to the c.-
819G>T locus and induce CysLTR2 gene expression. More-
over, PMA/ionophore-stimulated signaling may cause an
increase in this binding factor on the promoter, which
would induce greater CysLTR2 gene expression. With c.-
819T, PMA/ionophore-induced signaling may cause
higher-level binding of the DNA-binding factor than it
does with c.-819G, which would increase  CysLTR2 gene
expression. We performed a supershift assay for the candi-
date factors: SRY and HFH-2. Neither SRY nor FoxD3
(human homolog of HFH2) antibodies showed super-
shifts in EMSA. The nature of the putative DNA-binding
factor therefore remains to be clarified.
In the evaluation of the sequence variance of the 3'-UTR
(c.2078C>T and c.2534A>G) on CysLTR2 gene expression,
the former was chosen since the c.2534A>G is located 124
bp downstream from the polyadenylation site and would
not be present in mature mRNA. The expression level of
fluorescence containing the c.2078T type was significantly
higher than that of c.2078C (Figure 5). This indicates that
mRNA degradation of the T type of CysLTR2 3'-UTR was
much slower than that of the C type. Based on the results
of our promoter and 3'-UTR functional study, the
sequence variance of the two loci may influence CysLTR2
gene expression cooperatively. To validate the results of our
promoter and 3'-UTR functional study, we performed the
additional experiment using the vectors containing both
promoter and 3'-UTR regions of CysLTR2. Ht1 (c. -819 G
and c. 2078 C) and Ht2 (c. -819 T and c. 2078 T) were
inserted into pGL3-basic luciferase reporter system,
respectively. The expression level of luciferase containing
the ht2 was significantly higher than that of ht1, especially
when stimulated with PMA plus ionomycin (data not
shown). These results indicate that the combined genetic
differences affect the amount of protein and mRNA
expression in CysLTR2 gene. In contrast to the extensive
studies on the functions of the CysLT1 receptor [21,22],
the functional characterization of the CysLT2 receptor has
been limited because of a lack of specific competitive
antagonists. Recent experimental studies have demon-
strated unanticipated functions for the cysLTs, acting non-
redundantly through CysLTR2. CysLTR2, but not
CystLTR1, is the receptor responsible for mediating the
contribution of the CysLTs to experimental bleomycin-
induced chronic pulmonary inflammation and fibrosis
[23], and for the production of IL-8 by IL-4-primed cul-
tured human mast cells [24]. However, the impact of the
receptor has not been revealed in chronic inflammatory
airway diseases such as asthma. In particular, any in vivo
role for the CysLTR2 receptor remains unknown. To the
best of our knowledge, our study is the first to clearly dem-
onstrate the genetic relationship between the CysLTR2
receptor nucleotide polymorphism and aspirin hypersen-
sitivity in asthmatics at the level of gene function.BMC Medical Genetics 2009, 10:106 http://www.biomedcentral.com/1471-2350/10/106
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Conclusion
The sequence variants on the promoter and on the 3'-UTR
of CysLTR2 affect the efficiency of its transcription and the
stability of its mRNA, resulting in the alteration of protein
expression of CysLTR2. This change causes a certain
number of asthmatics to be susceptible to aspirin hyper-
sensitity. This functional evidence may have genetic value
as a diagnostic biomarker and could provide fundamental
information for the development of therapeutic strategies.
Methods
EV virus-infected B cell culture
Venous whole blood was obtained from asthmatics hav-
ing the haplotype 1 (common allele homozygotes (GCAA:
c.-819G>T, c.2078C>T, c.2534A>G and c.2545+297A>G)
and haplotype 2 (rare allele homozygotes (TTGG)) and
peripheral blood mononuclear cells (PBMC) were sepa-
rated using discontinuous Histopaque gradients solution
(Sigma, St. Louis, MO). PBMC were infected with B95-8
supernatant and incubated with 0.5 g/ml of cyclosporine
A (Sigma) for 3 weeks. Cells were cultured in RPMI 1640
(Invitrogen Life Technologies, Carlsbad, CA) supple-
mented with L-glutamine (2 mM), HEPES (25 mM), and
10% FBS (Invitrogen Life Technologies). All cell lines were
maintained in culture at 37°C in an atmosphere contain-
ing 5% CO2. Cells were reseeded at a density of 5 × 104
cells/ml every 3-4 days. This study was performed with the
approval of the Ethics Committee of the Soonchunhyang
University Hospital and informed written consent was
obtained from all the study subjects.
Flow cytometry analysis of CysLTR2 protein expression
The expression of CysLTR2 in B cell lines was assessed
with the use of a polyclonal anti-CysLTR2 antibody (Cay-
man Chemicals, Ann Arbor, MI) directed against amino
acids 1-18 of the N-terminal portion of the receptor. For
flow cytometry studies, B cell lines were washed twice
with PBS and labeled for 30 min at 4°C with anti-
CysLTR2 antibody (or irrelevant antibody for control).
Cells were then washed twice with PBS and incubated for
30 min at 4°C with FITC-conjugated goat anti-rabbit IgG
(BD Pharmingen™; BD Biosciences, San Diego, CA). As an
isotype-matched control, FITC-conjugated mouse IgG1
(BD Biosciences) was similarly treated. Finally, cells were
washed again and resuspended in PBS. An analysis of flu-
orescence staining was performed with a FACSCalibur
flow cytometer and Cell Quest Software (Counter Corpo-
ration, Miami, FL). The levels of CysLTR2 expression were
determined as the percentage of positive staining and the
ratio of mean FL1 channel values of CysLTR2 stain. The
percentage of positive staining was measured as the cells
showing fluorescence above that of the control antibody.
The ratio of mean FL1 channel values was determined as
the FL1 level of CysLTR2 stain to that of the isotype-
matched control stain.
Semi-quantitation of mRNA expression using reverse 
transcriptase polymerase chain reaction
Total RNA was extracted using TRI Reagent (guanidium
thiocyanate-phenol mixture; Molecular Research Center,
Inc., Cincinnati, OH) and chloroform. Possible DNA con-
tamination was eliminated by treatment with 1 l of
RNase-free DNase I (10,000 U/ml; Stratagene, La Jolla,
CA) for 15 min at 37°C. The reaction was stopped with
0.5 l of 2 mM EDTA. DNase I-treated RNA was heated at
65°C for 5 min with 1 l of oligo deoxythymidine-15
primer (500 g/ml) and 10 mM dNTP mix, then quickly
chilled on ice. After centrifugation, DNase I-treated RNA
were incubated at 42°C for 2 min with 0.1 mM DTT and
1 l of SuperScript II™ RT (200 U/l; Invitrogen Life Tech-
nologies) at 42°C for 50 min, and then heat inactivated at
70°C for 15 min. Following reverse transcription (RT),
cDNA was aliquoted into tubes containing specific primer
pairs (Table 1) for human CysLTR2 and GAPDH genes to
Table 1: Primer sequences used in this study
Approach Orientation Location Primer Sequence
RT-PCR
CysLTR2 Forward +29/+46 5'-CATCCATCTCCGTATCAG-3'
Reverse +734/+717 5'-GCCTTCCTGTGAGAAACC-3'
GAPDH Forward 5'-CGTCTTCACCATGGAGA-3'
Reverse 5'-CGGCCATCACGCCACAGTTT-3'
Promoter construct Forward -1342/-1323 5'-TTTTCCTGCCTTGTTGTTGG-3'
Reverse +178/+159 5'-TGGACAACCCATTTCCCAAG-3'
Nested, Forward -1008/-987 5'-ATTTAGCTAGCCAAAACATTAAATGTAACTTAG-3'
Nested, Reverse -4/-30 5'-ATTATCTCGAGGGGTTAAAAAGAAACAGACACAAAAAG-3'
UTR construct Forward +501/+517 5'-GGCTTCCTCAATAATGC-3'
Reverse +2787/+2770 5'-GGTTGACCAAATGCTGTG-3'
Nested, Forward +1042/+1062 5'-AAATAGCGGCCGCGGAGCTCTTAGATGAGACCTG-3'
Nested, Reverse +2410/+2385 5'-TTAATGCGGCCGCTTGGTAGGAAAGGACAGCTTTTATTC-3'
Underlined nucleotide sequences are added to the 5' end of oligonucleotide primer for cloning. These cloning sites are Nhe I (GCTAGC), Xho I 
(CTCGAG), and Not I (GCGGCCGC), and they are preceded by A and T residues at randomBMC Medical Genetics 2009, 10:106 http://www.biomedcentral.com/1471-2350/10/106
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amplify into 706-bp and 300-bp PCR products, respec-
tively. Amplification was performed on a thermocycler for
30 cycles (one cycle: 1 min at 95°C, 1 min at 55°C, and 1
min at 72°C) with the initial denaturation at 95°C for 5
min and a final extension at 72°C for 7 min. Amplified
PCR products were electrophoresed on a 1% agarose gel
and visualized by ethidium bromide staining.
Preparation of the promoter (c.-819T>G)-luciferase and 
the EGFP-3'-UTR (c.2078C>T) reporter constructs
The promoter and UTR region of CysLTR2 were amplified
by PCR. Primary PCR products were amplified using the
genomic DNA of allele-matched B cell lines as templates
from the CysLTR2 promoter (1520-bp fragment, from -
1342 to +178) and UTR (2287 bp fragment, from +501 to
+2787) sequence. The primary PCR reaction mixture was
diluted and used as a template for a nested PCR using the
nested primer. The secondary PCR primer for the pro-
moter (1027-bp fragments, from -1008 to -4) and UTR
(1395-bp fragments, from +1042 to +2410) region con-
tained a NheI-XhoI  and  NotI-NotI  restriction site. The
primers used are listed in Table 1. The amplified PCR
product was cloned into a pGEM-T easy vector (Promega,
Madison, WI) and digested with NheI and XhoI (New Eng-
land Biolabs, Beverly, MA). The fragment was subcloned
into the NheI and XhoI sites of a promoterless luciferase
reporter pGL3-Basic vector (Promega). The UTR fragment
was cloned into the NotI site of an enhanced green fluo-
rescent protein (EGFP) expression plasmid, pEGFP-N1
vector (BD Biosciences). Plasmids were isolated using the
Qiagen plasmid purification kit (Qiagen, Santa Clarita,
CA).
Transient transfection and assays of luciferase and 
fluorescence intensity
The 293 T cells were grown in Dulbecco's modified Eagle's
medium (Life Technologies, Rockville, MD) with L-
glutamine (2 mM), HEPES (25 mM), 10% heat-inacti-
vated FBS (Invitrogen Life Technologies), 100 U/ml peni-
cillin, and 100 ng/ml streptomycin (Life Technologies-
BRL, Gaithersburg, MD) at 37°C in humidified air con-
taining 5% CO2. One day before transfection, 5 × 105 cells
were seeded per well in 2 ml without antibiotics to obtain
90-95% confluence at the time of transfection. The 293 T
cells were then transiently transfected with pGL3-pro-
moter or pEGFP-UTR of the CysLTR2 gene using LF2000
(Invitrogen Life Technologies; recommended g DNA: l
lipofectamine = 1:2) in OptMEM (Life Technologies-BRL)
without serum. One microgram of pSV--galactosidase
control vector (Promega) was co-transfected to normalize
transfection efficiencies. For promoter construct transfec-
tion, PMA (10 ng/ml) and ionomycin (2 M) was added
for 24 h after transfection. After 48 h of transfection, cul-
tured cells were washed twice with PBS and solubilized by
scraping with 400 l of reporter lysis buffer (Promega).
Cells were centrifuged and the supernatant was stored at -
70°C. -galactosidase activities were assessed by ortho-
nitrophenyl-D-galactopyranoside (ONPG) hydrolysis
using a -Galactosidase Enzyme Assay System Kit
(Promega) and total protein was measured using a BCA
protein assay kit (Pierce, Rockford, IL). Luciferase activity
was measured using the Luciferase Assay System
(Promega) by a Turner 20/20 n luminometer (Turner Bio-
Systems, Inc., Sunnyvale, CA) and expressed as relative
luciferase activity to that of empty pGL3-basic vector. The
expression levels of EGFP with the 3'-UTR of CysLTR2
were assessed by measuring the mean channel values of
FL1 in flow cytometry (BD Biosciences) at 48 h after trans-
fections. The relative mean value of FL1 was calculated as
described above. The ratio of mean FL1 channel values
was determined as the FL1 level of the transfectant stain to
that of the isotype-matched control stain.
Nuclear extract preparation and electrophoretic mobility 
shift assays (EMSA)
Nuclear extracts were prepared by the modified method of
Schreiber et al. [25]. The PMA and ionomycin stimulated
B cell lines and unstimulated B cell lines were harvested
after washing twice with HBSS. Cells were washed with
buffer A (10 mM HEPES, 15 mM KCl, 2 mM MgCl2, 0.1
mM EDTA, 1 mM DTT, 0.5 mM PMSF, 10 g/ml leupep-
tin, 10 g/ml aprotinin; Calbiochem, La Jolla, CA). The
cell pellet was resuspended in buffer B (buffer A contain-
ing 0.2% Nonidet P-40) and incubated for 10 min. Nuclei
were pelleted by centrifugation and resuspended in buffer
C (buffer A containing 0.25 M sucrose). Nuclei were again
pelleted, then resuspended in buffer D (50 mM HEPES,
400 mM KCl, 10% glycerol, 0.1 mM EDTA, 1 mM DTT,
0.5 mM PMSF, 10 g/ml leupeptin, 10 g/ml aprotinin;
Calbiochem) and incubated with shaking for 30 min. All
procedures were performed on ice. The mixture was cen-
trifuged, and the supernatant was stored at -70°C. DNA-
protein binding assays were performed using the Gel Shift
Assay System (Promega) following the manufacturer's
instructions. Ten-microgram aliquots of nuclear extracts
were incubated in 10 l of total reaction volume contain-
ing binding buffer (Promega) for 10 min with or without
unlabeled oligonucleotide probe. The 32P-labeled oligo-
nucleotide probe was added to the reaction mixture and
then incubated for 20 min. The reaction products were
analyzed by electrophoresis in a 4% polyacrylamide gel
with 0.5× TBE buffer. Gels were dried and analyzed by
autoradiography. The sequences of the oligonucleotide
probes used were forward: 5'-TTTTG TTTTG TTGTT [G/
T]TTTT TTTTT TTTTT G-3', reverse: 5-CAAAA AAAAA
AAAAA [C/A]AACA ACAAA ACAAA A-3. To determine the
specificities of the DNA-protein complexes, 1.75 pmol of
unlabeled probe was incubated with the nuclear extract
for 10 min before the addition of the labeled probe. For
the supershift assay, 200 g of goat anti-human SRY AbBMC Medical Genetics 2009, 10:106 http://www.biomedcentral.com/1471-2350/10/106
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(Santa Cruz Biotechnology, Santa Cruz, CA) or goat anti-
human FoxD3 Ab (Santa Cruz Biotechnology) was incu-
bated with the nuclear extract for 30 min before the addi-
tion of the labeled probe.
Statistical analysis
Data are expressed as the mean ± standard error of the
mean (SEM). The program SPSS (version 10.0; SPSS Inc.,
Chicago, IL) was used for all analyses. Differences
between independent groups and samples were compared
using the nonparametric Kruskal-Wallis H-test for contin-
uous data. If significant differences were found, a Mann-
Whitney  U-test was applied to compare differences
between two samples. Wilcoxon's signed-ranks test was
used for two related samples.
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